Evidence map›Paper›PMID 38729623›Full record

ArticleJournal of medicinal chemistry2024

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility.

Antonio Romero, Luke Ashcraft, Aroop Chandra, Vincent DiMassa, Peadar Cremin, Scott E Collibee, Chihyuan Chuang, James Hartman, Darren T Hwee, David St Jean and 10 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Cardiac Troponin ActivatorJournal of medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Antonio RomeroCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.ORCID 0009-0003-6465-066X
Luke AshcraftCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Aroop ChandraCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Vincent DiMassaCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Peadar CreminCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Scott E CollibeeCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Chihyuan ChuangCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
James HartmanCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Darren T HweeCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
David St JeanCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Justin MalinowskiCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Mikkel DeBenedettoCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
David MoebiusCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Joshua PayetteCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Richard VargasCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
John YeomanCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Alykhan MotaniCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Jeffrey ReaganCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Fady I MalikCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.
Bradley P MorganCytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac myosin activation has been shown to be a viable approach for the treatment of heart failure with reduced ejection fraction. Here, we report the discovery of nelutroctiv (

Indexed as

Myocardial ContractionAnimalsCardiovascular DiseasesDrug DiscoveryHumansMaleMiceRatsRats, Sprague-DawleyStructure-Activity RelationshipSulfonamidesTroponinSulfonamidesTroponin

Identifiers

PMID38729623
PMCPMC11129190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.